Cholesterol alterations in fragile X syndrome, autism spectrum disorders and other neurodevelopmental disorders
Authors:
- 16 September 2023
- book chapter
- Published by Elsevier
- Vol. 173, 115-139
Abstract
No abstract availableKeywords
This publication has 113 references indexed in Scilit:
- Activation of Rho GTPases in Smith–Lemli–Opitz syndrome: pathophysiological and clinical implicationsHuman Molecular Genetics, 2010
- A new method for measurement of total plasma PCSK9: clinical applicationsJournal of Lipid Research, 2010
- Fifty years of advances in bile acid synthesis and metabolismJournal of Lipid Research, 2009
- Central nervous system: cholesterol turnover, brain development and neurodegenerationBiological Chemistry, 2009
- Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptorProceedings of the National Academy of Sciences, 2008
- Regulation of Sterol Synthesis in EukaryotesAnnual Review of Genetics, 2007
- Molecular Characterization of Loss-of-Function Mutations in PCSK9 and Identification of a Compound HeterozygoteThe American Journal of Human Genetics, 2006
- Mutations in PCSK9 cause autosomal dominant hypercholesterolemiaNature Genetics, 2003
- Absence of expression of the FMR-1 gene in fragile X syndromeCell, 1991
- Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndromeCell, 1991